-
公开(公告)号：US5716777A
公开(公告)日：1998-02-10
申请号：US448217
申请日：1995-05-23
申请人： Anne Grete Byskov , Claus Yding Andersen , Lars Nordholm , Henning Th.o slashed.gersen , Ole Wassmann , Ivan Verner Diers , Erling Guddal
发明人： Anne Grete Byskov , Claus Yding Andersen , Lars Nordholm , Henning Th.o slashed.gersen , Ole Wassmann , Ivan Verner Diers , Erling Guddal
IPC分类号： A61K31/575 , A61K20060101 , A61P13/02 , A61P15/00 , A61P15/08 , C07C20060101 , C07J9/00 , C07J43/00 , C07J51/00 , C07J53/00 , A01N45/00 , A01N1/02 , A61B17/43
CPC分类号： C07J43/003 , C07J51/00 , C07J53/001 , C07J9/00
摘要： The present invention relates to certain sterol derivatives for use as medicaments.
摘要翻译： 本发明涉及用作药物的某些固醇衍生物。
-
公开(公告)号：US09353172B2
公开(公告)日：2016-05-31
申请号：US14233455
申请日：2012-07-09
CPC分类号： A61K47/48284 , A61K38/24 , A61K47/60 , A61K47/643 , A61K47/644 , A61K47/68 , C07K14/59 , C07K14/76 , C07K2319/31
摘要： The present invention relates to a long acting biologically active luteinizing hormone (LH) compound comprising an LH agonist linked to a pharmaceutically acceptable molecule providing an in vivo plasma half-life of the LH agonist or LH compound which is increased substantially compared to the in vivo plasma half-life of an LH agonist administered in the same manner as the LH compound. The present invention relates to methods for controlled ovarian stimulation which can be used in conjunction with assisted reproduction technologies such as in vitro fertilization, intra cytoplasmatic sperm injection, intra uterine insemination and in vitro maturation. In other aspects the invention relates to methods for inducing folliculogenesis and methods for providing luteal support for the corpora lutea.
摘要翻译： 本发明涉及一种长效生物活性黄体生成激素（LH）化合物，其包含与药学上可接受的分子连接的LH激动剂，所述LH激动剂提供LH激动剂或LH化合物的体内血浆半衰期，其与体内相比大大增加 以与LH化合物相同的方式施用LH激动剂的血浆半衰期。 本发明涉及用于受控卵巢刺激的方法，其可以与辅助生殖技术如体外受精，细胞内精子注射，子宫内子宫内受精和体外成熟结合使用。 在其他方面，本发明涉及诱导卵泡发生的方法以及为黄体提供黄体支持的方法。
-
3.发明授权Synchronization of the cytoplasmatic and the nuclear maturation of oocytes in vitro 失效体外同步化卵母细胞的细胞质和核成熟公开(公告)号：US07192768B2
公开(公告)日：2007-03-20
申请号：US10263955
申请日：2002-10-03
IPC分类号： C12N5/00
CPC分类号： C12N5/0609
摘要： The present invention relates to a method for in vitro maturation of oocytes comprising the steps of: (a) culturing one or more GV oocytes in a culture medium, the culture medium comprising a nuclear maturation inhibiting substance and comprising one or more gonadotropins and/or one or more growth factors, the culturing taking place for a time period sufficient for cytoplasmatic maturation to occur; (b) washing the GV oocytes of step (a) to remove the nuclear maturation inhibiting substance; (c) culturing the washed oocytes of step (b) in a culture medium comprising one or more gonadotropins and/or one or more growth factors and/or MAS for a time period sufficient for nuclear maturation. The invention also relates to an oocyte culture medium comprising a nuclear maturation inhibiting substance and comprising one or more gonadotropins and/or one or more growth factors. The nuclear maturation inhibiting substance may be a MAS antagonist or an FF-MAS synthesis inhibitor, preferably a cytochrome P450 lanosterol 14α-demethylase (P45014DM) inhibitor e.g. ketoconazole or 22-hydroxycholesterol. The one or more gonadotropins and/or one or more growth factors are preferably a combination of EGF and FSH and/or LH.The invention also relates to the use of a nuclear maturation inhibiting substance and one or more gonadotropins and/or one or more growth factors as described above for the preparation of a cell culture medium for in vitro maturation of oocytes.
摘要翻译： 本发明涉及卵母细胞体外成熟的方法，包括以下步骤：（a）在培养基中培养一种或多种GV卵母细胞，所述培养基包含核成熟抑制物质并包含一种或多种促性腺激素和/或 一个或多个生长因子，培养发生足以发生细胞质成熟的时间段; （b）洗涤步骤（a）的GV卵母细胞以去除核成熟抑制物质; （c）在包含一种或多种促性腺激素和/或一种或多种生长因子和/或MAS的培养基中培养步骤（b）的洗涤的卵母细胞足以进行核成熟的时间段。 本发明还涉及包含核成熟抑制物质并包含一种或多种促性腺激素和/或一种或多种生长因子的卵母细胞培养基。 核成熟抑制物质可以是MAS拮抗剂或FF-MAS合成抑制剂，优选细胞色素P450羊毛甾醇14α-脱甲基酶（P45014DM）抑制剂。 酮康唑或22-羟基胆固醇。 一种或多种促性腺激素和/或一种或多种生长因子优选是EGF和FSH和/或LH的组合。 本发明还涉及如上所述的核成熟抑制物质和一种或多种促性腺激素和/或一种或多种生长因子用于制备卵母细胞体外成熟的细胞培养基的用途。
-
公开(公告)号：US20140228292A1
公开(公告)日：2014-08-14
申请号：US14233455
申请日：2012-07-09
CPC分类号： A61K47/48284 , A61K38/24 , A61K47/60 , A61K47/643 , A61K47/644 , A61K47/68 , C07K14/59 , C07K14/76 , C07K2319/31
摘要： The present invention relates to a long acting biologically active luteinizing hormone (LH) compound comprising an LH agonist linked to a pharmaceutically acceptable molecule providing an in vivo plasma half-life of the LH agonist or LH compound which is increased substantially compared to the in vivo plasma half-life of an LH agonist administered in the same manner as the LH compound. The present invention relates to methods for controlled ovarian stimulation which can be used in conjunction with assisted reproduction technologies such as in vitro fertilisation, intra cytoplasmatic sperm injection, intra uterine insemination and in vitro maturation. In other aspects the invention relates to methods for inducing folliculogenesis and methods for providing luteal support for the corpora lutea.
摘要翻译： 本发明涉及一种长效生物活性黄体生成激素（LH）化合物，其包含与药学上可接受的分子连接的LH激动剂，所述LH激动剂提供LH激动剂或LH化合物的体内血浆半衰期，其与体内相比大大增加 以与LH化合物相同的方式施用LH激动剂的血浆半衰期。 本发明涉及用于受控卵巢刺激的方法，其可以与辅助生殖技术如体外受精，细胞内精子注射，子宫内子宫内受精和体外成熟结合使用。 在其他方面，本发明涉及诱导卵泡发生的方法以及为黄体提供黄体支持的方法。
-
-
-
搜索结果
4 条记录 (耗时 0.014 秒)
